Can MRK's New Drugs & Pipeline Aid Long-Term Growth Post Keytruda LOE?

Merck bets on newer drugs, pipeline candidates and M&A deals to offset looming Keytruda patent expiry and drive long-term growth.

Zacks Investment Research • May 29, 2026

FDA Grants Breakthrough Therapy Designation for Calderasib (MK-1084), an Investigational KRAS G12C Inhibitor, for Certain Patients with Newly Diagnosed Metastatic KRAS G12C-Mutant Non-Small Cell Lung Cancer (NSCLC)

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that calderasib (MK-1084), an investigational oral specific KRAS G12C inhibitor, in combination with KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, has been granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA) for the first-line treatment of patients with advanced or metastatic non-small cell lung cancer (NSCLC) with KRAS G12C-mutation and e.

Business Wire • May 29, 2026

Here is What to Know Beyond Why Merck & Co., Inc. (MRK) is a Trending Stock

Recently, Zacks.com users have been paying close attention to Merck (MRK). This makes it worthwhile to examine what the stock has in store.

Zacks Investment Research • May 28, 2026

Merck to Participate in the Jefferies Global Healthcare Conference

RAHWAY, N.J.--(BUSINESS WIRE)--Merck to Participate in the Jefferies Global Healthcare Conference.

Business Wire • May 28, 2026

Merck chicken bronchitis vaccine approved for use in China

Merck said its vaccine against bronchitis in chickens has ​been approved by the Chinese ‌agriculture ministry for use in the world's largest chicken-rearing country, which is ​home to over 5 ​billion birds.

Reuters • May 27, 2026

Merck and Mastercard are seeing real agentic AI results. Both say the plumbing came first.

Merck is using AI agents to cut drug discovery cycles by a third and ship compliant marketing materials up to 80% faster — but VP of Digital Platforms Sean Finnerty says the only reason it's working is because they built the infrastructure first. And the pharmaceutical manufacturer is seeing promising early results: AI is generating marketing drafts that are “99% right” when it comes to compliance, shrinking review cycles from months to days and accelerating delivery by 70% to 80%.

VentureBeat • May 27, 2026

Baron Health Care Fund Q1 2026 Portfolio Activity

During the quarter, we added 9 new positions and exited 11 positions, bringing the number of positions in the Fund to 41. We reacquired shares of Natera, Inc., a diagnostics company that provides testing services in the oncology, prenatal, and organ transplant settings. We added to the Fund's investment in BillionToOne, Inc., a diagnostics company that is disrupting the market with more accurate prenatal and oncology genetic tests.

Seeking Alpha • May 27, 2026

Merck Announces Third-Quarter 2026 Dividend

RAHWAY, N.J.--(BUSINESS WIRE)--Merck Announces Third-Quarter 2026 Dividend.

Business Wire • May 26, 2026

MRK Stock Gains After CHMP Backs Keytruda Combo for Bladder Cancer

Merck jumps after CHMP backs Keytruda plus Padcev for certain bladder cancer patients, a combo with the potential to expand treatment options.

Zacks Investment Research • May 25, 2026

Merck Stock Zooms Closer To A Breakout On 'A New Chapter' In Cancer

Merck stock popped early Friday after European officials recommended approving its combination for a form of bladder cancer.

Investors Business Daily • May 22, 2026